– Listing on the new “Sparks”
segment of SIX Swiss Exchange for small and medium-sized companies is planned
for Q1 2022, subject to market environment
– Xlife Sciences AG is a Swiss company focused
on the value development and commercialization of promising research projects
from universities and other research institutions in the field of life sciences
– The company is involved as incubator and
accelerator in in 23 project companies until the successful exit after the
proof-of-concept phase with the goal of participating in their
long-term value development
– Xlife Sciences is currently listed on the
Munich Stock Exchange and has a market capitalization of EUR 233 million as per
end of 2021.
SWITZERLAND – EQS Newswire – 10 January 2022 – Xlife
Sciences AG (XLS DE) confirms its intention to be listed on SIX Swiss Exchange,
as communicated in November 2021. Subject to market environment, the listing on
the new “Sparks” segment of SIX Swiss Exchange is still planned for
Dr. Bernhard Scholz, Chairman of the Board of Xlife Sciences, comments:
“Switzerland has a strong and dynamic life sciences industry and
correspondingly knowledgeable investors and analysts. The new Sparks segment of
the Swiss stock exchange is attractive for Xlife Sciences as an emerging growth
company and should further increase our visibility and market
Oliver R. Baumann, CEO of Xlife Sciences, added: “With the planned
listing in Switzerland and the accompanying move to a regulated market, we aim
to make our company more accessible to institutional investors, increase the
liquidity of the stock and further enhance the transparency of Xlife
Xlife Sciences is a Swiss company focused on the value development and
commercialization of promising research projects from universities and other
research institutions in the field of life sciences. The goal is to bridge the
gap from research and development to healthcare markets.
Xlife Sciences brings carefully selected early-stage projects in the four
areas of technological platforms, biotechnology/therapies, medical technology,
and artificial intelligence/digital health to the next stage of development.
The focus is on preclinical projects in biotechnology that are acquired with a
successful spin-off by a university, a clinical center, or a research
institution. Currently, eleven employees and eight consultants work for Xlife
Sciences AG; across all project companies, there are more than 120 scientific
employees, researchers, and project managers in total.
The team of Xlife Sciences has proven experience in the life sciences sector
thanks to the many years of expertise in successful partnering of the company
founders and the scientific advisory board. In addition to Chairman Dr.
Bernhard Scholz, the Board of Directors comprises Christian Faber, Prof. Dr.
habil. Michael B. Klein, Mark S. Müller, and Simon Schöni. The Management Team
consists of CEO Oliver R. Baumann (also member of the Board of Directors), CFO
Carl von Halem, Chief Scientific Officer (CSO) Frank Plöger, and Beat Kläui as
Head of Accounting & Taxation.
The Value Chain
Xlife Sciences generally focuses its involvement in a project on the early
phase, i.e., until completion of the so-called “proof-of-concept”
phase, and subsequently strives to commercialize the project company, e.g.,
through a sale of the company or individual product candidates (“trade
sale”), through out-licensing of products or patents, or through an IPO of
the project company. This strategy enables Xlife Sciences to realize an
increase in value already after the proof-of-concept phase. Potential future
growth opportunities are also captured with possible milestone payments and
royalties in the later market phase.
The Project Companies
Xlife Sciences cooperates with 15 prominent universities and research
institutes from Germany and Switzerland, and reviews invention disclosures and
project ideas in a thorough and structured three-step due-diligence process. If
Xlife Sciences decides to take over the invention disclosure, usually a
separate project company is founded for this purpose and prepared for the
possible exit after a successful proof-of-concept phase (2-3 years). In
addition, these companies are supported in positioning, structuring, and
implementing their concepts, for example by providing management services.
Furthermore, Xlife Sciences aims to create and exploit synergies between the
Currently, the portfolio of Xlife Sciences comprises 23 project companies.
Five project companies are based in Switzerland, the others mostly in Germany.
According to the current assessment of the Management Team, the project
companies Veraxa Biotech, Laxxon Medical, Lysatpharma, Quadira Biosciences,
Saniva, Vitruvia, Synimmune, Ix Therapeutics, and Baliopharm are among the
short- and medium-term growth drivers of Xlife Sciences. These growth drivers
can be, for example, an exit, the completion of the preclinical development
phase, further commitments of federal funds or even the first-time revenue
Planned listing on SIX Swiss Exchange
Currently, the company is admitted to trading on the Munich Stock Exchange
(unregulated market [“Freiverkehr”] in the segment m:access) with a
market capitalization of EUR 233 million as of the end of 2021. Concurrently
with the listing on SIX Swiss Exchange on the new “Sparks” segment,
trading of the shares of Xlife Sciences AG on the Munich Stock Exchange shall
be ceased for regulatory reasons. The shares will be tradeable on SIX Swiss
Exchange after the switch to SIX Swiss Exchange.
Following the intended listing on SIX Swiss Exchange, the proportion of
freely tradable shares (“free float”) is expected remain at
approximately 44%, the current quota on the Munich Stock Exchange. The majority
of the shares will continue to be held by the two founders as well as the
members of the Board of Directors and management team.
Since October 1, 2021, fast-growing, small and medium-sized enterprises
(SMEs) have been able to list on the “Sparks” segment of SIX Swiss
Exchange. This is a regulated trading segment tailored to the requirements of
SMEs and their investors. Among other things, the segment provides for easier
access for younger companies and a condensed trading window. Apart from that,
SMEs are subject to the same prospectus requirements, the same regulatory
oversight and the same reporting requirements as companies traded on the main
segment of SIX Swiss Exchange.